Is Pegasys Used for Hepatitis C?
Yes, Pegasys (peginterferon alfa-2a) treats chronic hepatitis C virus (HCV) infection in adults and children over age 5. It works by boosting the immune response against the virus, often combined with ribavirin or other antivirals.[1]
How Is Pegasys Given for Hep C?
Pegasys is injected subcutaneously once weekly for 24 to 48 weeks, depending on genotype and response. Dosing starts at 180 mcg for adults. It's no longer first-line due to direct-acting antivirals (DAAs) like sofosbuvir, which cure >95% of cases with shorter treatment.[1][2]
Why Isn't Pegasys First Choice Anymore?
DAAs replaced interferon-based regimens like Pegasys after 2014 FDA approvals. Pegasys has more side effects—flu-like symptoms, depression, anemia, thyroid issues—and lower cure rates (40-80% vs. DAAs' near-100%). Guidelines from AASLD/IDSA recommend DAAs alone.[2]
What Happens If You Still Use Pegasys Today?
It's used off-label or in resource-limited settings where DAAs cost too much. Genotype matters: effective for 1-6, but resistance and cirrhosis complicate outcomes. Monitor blood counts weekly.[1]
Common Side Effects Patients Report
Fatigue (60%), headache (50%), fever (45%), muscle pain (40%), irritability (30%). Neuropsychiatric risks include suicide ideation (1-2%). Ribavirin combo adds hemolytic anemia.[1][2]
Alternatives to Pegasys for Hep C
| Treatment | Cure Rate | Duration | Key Difference |
|-----------|-----------|----------|---------------|
| Epclusa (sofosbuvir/velpatasvir) | 98-99% | 12 weeks | Oral, pangenotypic, minimal sides |
| Mavyret (glecaprevir/pibrentasvir) | 98% | 8 weeks | Shortest course, no cirrhosis limit |
| Harvoni (ledipasvir/sofosbuvir) | 96-99% | 8-12 weeks | Genotype 1 specialist |
These DAAs dominate; Pegasys phased out in high-income countries.[2]
Patent and Availability Status
Pegasys patent expired in 2020 in the US, allowing generics. Check DrugPatentWatch.com for exact expiry dates and litigation by region.[3]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103964s512lbl.pdf
[2] AASLD/IDSA Guidelines: https://www.hcvguidelines.org/
[3] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/PEGASYS